Center for Translational Pediatric Research (CTPR)

项目摘要 SARS-CoV-2变种的持续出现和随后在世界各地的传播令人担忧 为全球控制冠状病毒病（COVID-19）大流行的努力。尽管负担沉重， 总体而言，阿肯色州在对该州感染相关病毒进行测序方面进展缓慢。为此 我们的转化儿科研究中心（CTPR）生物医学研究卓越中心 （COBRE）和阿肯色州IDEA生物医学研究卓越网络（INBRE）合作， 为阿肯色州提供可持续的SARS CoV-2基因组监测数据和分析。为核心 根据这项提议，我们建立了一个强大的合作组织，名为阿肯色州测序（ArkSeq）联盟 其中包括阿肯色州大学医学科学（UAMS），阿肯色州儿童医院（ACH）， 包括阿肯色州儿童西北和UAMS西北扩展，浸信会健康（BH）在小石城， 由阿肯色州卫生部（ADH）和阿肯色州管理的全州免下车购物中心 儿童研究所（阿克里）。该联盟提供残留病毒转运培养基（VTM）， 被确认为SARS冠状病毒2型阳性我们的目标是持续监测这些样本是否有严重急性呼吸系统综合症- CoV-2序列多样性和病毒传播动力学，并为ADH和CDC提供可操作的数据 关于变种。该提案的目的1是为阿肯色州提供基因组监测。为了实现这一目标，我们 我们将使用基于Illumina的平台对来自ArkSeq联盟的至少12288个样本进行测序， 值得关注的（VoCs），目标是扩展到所有患者。我们将获得以下临床信息： 这些样本，包括受试者的人口统计学资料（年龄、性别、种族、民族、居住县和邮编 代码）、采集日期、采样时的症状、采样时存在的其他呼吸道病毒 阳性结果和接种状态（疫苗类型和接种日期）。这种方法将使我们能够 回答研究问题：“在阿肯色州不同变异的相对水平是多少？";“怎么样？ 这种变化随着时间的推移？”以及“不同的阿肯色州变体如何分布在不同的地理区域， 区域以及种族、族裔、性别和/或年龄组之间的差异？”与ADH和CDC合作， 我们将把来自阿肯色州的VOC和其他血统整合到国家数据库中。我们计划提供可操作的 目前在阿肯色州流行的SARS-CoV-2毒株的测序信息。满足这一 为了实现这一目标，我们目前正在参加与CDC的每周SPHERES电话会议，并与ADH合作 和ArkSeq合作伙伴每月举行一次关于已识别变体的会议。在成功完成此 根据这项提议，我们将向数据库提供比目前多21倍的来自阿肯色州的序列 可从我们的国家，与许多其他样品保持为未来的评估。

PROJECT SUMMARY The continuing emergence and subsequent circulation of SARS-CoV-2 variants across the world is of concern for the global effort of controlling the Coronavirus Disease (COVID)-19 pandemic. Despite a high-burden of disease overall, Arkansas has been slow to sequence viruses associated with infections in the state. For this proposal, our Center for Translational Pediatric Research (CTPR) Center of Biomedical Research Excellence (COBRE) and Arkansas IDeA Network of Biomedical Research Excellence (INBRE) have partnered together to deliver sustainable SARS CoV-2 genomic surveillance data and analyses for the State of Arkansas. At the core of this proposal, we have built a powerful collaboration named the Arkansas Sequencing (ArkSeq) Consortium which includes the University of Arkansas for Medical Sciences (UAMS), Arkansas Children’s Hospital (ACH), including Arkansas Children’s Northwest and UAMS Northwest extensions, Baptist Health (BH) in Little Rock, drive-through centers across the State run by the Arkansas Department of Health (ADH), and Arkansas Children’s Research Institute (ACRI). This consortium provides remnant viral transport media (VTM) that have been identified as positive for SARS-CoV-2. Our objective is to continuously monitor these samples for SARS- CoV-2 sequence diversity and viral phylodynamics and to provide actionable data back to the ADH and CDC regarding variants. Aim 1 of this proposal is to provide genomic surveillance for Arkansas. To fulfill this aim, we will use Illumina-based platforms to sequence at least 12288 samples from our ArkSeq Consortium for variants of concern (VoCs) over the next year with a goal to scale to all patients. We will obtain clinical information on these samples, including the subject’s demographics (age, sex, race, ethnicity, county of residence, and zip code), date of collection, symptoms at the time of sampling, other respiratory viruses present at the time of positive result, and vaccination status (vaccine type and date of vaccination). This approach will allow us to answer the research questions: “What are the relative levels of the different variants in Arkansas?”; “How does this change over time?” and “How are different Arkansas variants distributed across different geographical regions, as well among racial, ethnic, gender, and/or age groups?” In collaboration with the ADH and the CDC, we will integrate VoCs and other lineages from Arkansas into national databases. We plan to provide actionable sequencing information on current strains of SARS-CoV-2 that are circulating within Arkansas. To meet this goal, we are currently participating in the weekly SPHERES calls with CDC, and we are partnering with ADH and ArkSeq partners to have monthly meetings regarding identified variants. Upon successful completion of this proposal, we will have provided ~21 times more sequences from Arkansas to the databases than are currently available from our State, with many other samples maintained for future evaluation.